Key result
Combination therapy with a CTLA-4 inhibitor and a PD-1 or PD-L1 inhibitor increases the risk of developing immune checkpoint inhibitor-associated myocarditis.
Why the study?
Immune checkpoint inhibitor-associated myocarditis is a significant and potentially fatal adverse effect, presenting new diagnostic and therapeutic challenges for practicing clinicians.
This review outlines a standardized, multimodality diagnostic and therapeutic approach for managing the potentially fatal complication of immune checkpoint inhibitor-associated myocarditis.
Answers are grounded in this paper and cite their sources.
Demands heightened vigilance for ICI myocarditis in cancer care; leaves open standardized diagnostic and therapeutic protocols.
Importance: In the last decade, immune checkpoint inhibitors (ICIs) have been approved for the treatment of many cancer types. Immune checkpoint inhibitor-associated myocarditis has emerged as a significant and potentially fatal adverse effect. Recognizing, diagnosing, and treating ICI-associated myocarditis poses new challenges for the practicing clinician. Here, the current literature on ICI-associated myocarditis is reviewed. Observations: Clinical presentation and cardiac pathological findings are highly variable in patients with ICI-associated myocarditis. Although endomyocardial biopsy is the criterion standard diagnostic test, a combination of clinical suspicion, cardiac biomarkers (specifically troponin), and cardiac imaging, in addition to biopsy, is often needed to support the diagnosis. Importantly, the combination of a cytotoxic T-lymphocyte-associated protein 4 inhibitor with a programmed cell death protein 1 or programmed death-ligand 1 inhibitor increases the risk of developing ICI-associated myocarditis. Conclusion and Relevance: This review aims to provide a standardized diagnostic and therapeutic approach for patients with suspected ICI-associated myocarditis. A complete history of recent cancer treatments and physical examination in combination with cardiac biomarkers, cardiac imaging, and endomyocardial biopsy represent a pragmatic diagnostic approach for most cases of ICI-associated myocarditis. The addition of novel biomarkers or imaging modalities is an area of active research and should be evaluated in larger cohorts.
No takes yet. Share an insight, caveat, or question.
Lehmann et al. (2021) conducted a review in Immune checkpoint inhibitor-associated myocarditis. Immune checkpoint inhibitors was evaluated. Combination therapy with a CTLA-4 inhibitor and a PD-1 or PD-L1 inhibitor increases the risk of developing immune checkpoint inhibitor-associated myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: